Brand generic name: Minoo Haloperidol®
Pharmacotherapeutic group: Antipsychotic & Phenylbutyl piperadine derivative & Dopaminergic blocking agent
Therapeutic indication: Psychotic disorder & Behavior problems & Gills de la Tourette’s syndromes & Autism & chorea Huntington’s & Nausea and vomiting cancer chemotherapy
Dosage and Administration: Tablet 0.5mg
Antipsychotic:
Adult: oral; initially 0.5mg to 5mg two or three times a day, the dosage being adjusted as needed and tolerated.
Pediatric 3 to12 years: oral; initially 0.05mg/kg a day ( in two or three divided doses), the daily dose being increased as needed and tolerated by 0.5mg increments at five to seven day intervals up to a total of 0.15mg/kg a day.
Side effect: Akathisia, dystonic, extrapyramidal effects, allergic reaction, anticholinergic effects, CNS effects, decreased thirst, unusual tiredness or weakness, orthostatic hypotension, persistent tardive dyskinesia, neuroleptic malignant syndrome, blurred vision, change in menstrual period, constipation, dryness of mouth, swelling or soreness in breasts in females, unusual secreation of milk, weight gain, decreased sexual ability, drowsiness, increased sensitivity of skin to sun, nausea or vomiting
Information on the shelf life: 5 years

Generic name: Fluvoxamine

Brand generic name: Minoo Fluvoxamine®

Pharmacotherapeutic group: Antidepressant & Selective serotonin reuptake inhibitor

Therapeutic indication: Obsessive-compulsive disorder & major depressive disorder & autism & panic disorder & social phobia & generalized anxiety disorder & post-traumatic stress disorder & premenstrual dysphoric disorder

Dosage and Administration: Tablet 50mg

Adult: oral; initially 50mg in a single dose at bedtime. The dosage may be increased as needed and tolerated in increments of 50mg a day at intervals of four to seven days (Max doses 300mg/d). If the daily dosage exceeds 100mg, it should be taken in two divided doses.

Pediatric 8 to17 years: oral; initially 25mg in a single dose at bedtime. The dosage may be increased as needed and tolerated in increments of 25mg a day at intervals of four to seven days (Max doses 200mg/d). If the daily dosage exceeds 50mg, it should be taken in two divided doses.

Pediatric younger than 8 years: Safety and efficacy have not been established.

Side effect: Sexual dysfunction, anorgasmia, decreased libido or impotence, asthenia or fatigue, constipation, dizziness, headache, insomnia, nausea, vomiting, abdominal pain, anorexia, diarrhea, dryness of mouth, dyspepsia, increased sweating, palpitation, tremor, urinary frequency vertigo

Information on the shelf life: 2 years

Pharmacotherapeutic group: Antidepressant & Selective serotonin reuptake inhibitor

Therapeutic indication: Major depressive disorder & Obsessive-compulsive disorder & Panic disorder & social phobia & post-traumatic stress disorder & premenstrual dysphoric disorder

Dosage and Administration: Tablet 50mg &100 mg

Depression or obsessive-compulsive disorder:

Adult: oral; initially 50mg a day as a single morning or evening dose. The dosage may be increased after several weeks in increments of 50mg, with increased made at intervals of at least one week, as needed and tolerated.

Panic disorder:

Adult: oral; initially 25mg a day as a single morning or evening dose. After one week, the dosage should be increased to 50mg a day, as a single dose. Further dosage increases may be made in increments of 50mg, at intervals of at least one week, as needed and tolerated.

Depression or Panic disorder:

Pediatric: Safety and efficacy have not been established.

Obsessive-compulsive disorder:

Pediatric 13 to17 years: oral; initially 50mg a day as a single morning or evening dose. Dosage may be increased at intervals of at least one week, as needed and tolerated.

Pediatric 6 to13 years: oral; initially 25mg a day as a single morning or evening dose.

Dosage may be increased at intervals of at least one week, as needed and tolerated.

Side effect: Sexual dysfunction, dizziness, drowsiness, gastrointestinal effects, diarrhea or loose stools, dryness of mouth, nausea, stomach or abdominal cramps or gas or pain, weight loss, headache, increased sweating, insomnia, tiredness or weakness, tremor

Information on the shelf life: 2 years

Generic name: Thioridazine Hydrochloride

Brand generic name: MinooThioridazine ®

Pharmacotherapeutic group: Phenothiazine derivative & Antipsychotic & Dopaminergic blocking agent

Therapeutic indication: Psychotic disorders & Psychoneurotic manifestations & Behavior disorders pediatric & Huntington’s disease

Dosage and Administration: Tablet 10mg & 25mg & 100mg

Adult: Initial: Oral, 50 to 100mg one to three times per day, the dosage being adjusted gradually as needed and tolerated.

Maintenance: oral, 50 to 200mg two to four times per day.

Pediatric 2 to 12 years: Initial: Oral, 10 to 25mg two or three times per day, the dosage being adjusted gradually as needed and tolerated; the usual dosage rang is 0.25mg to 3mg/kg four times per day.

Pediatric up to2 years: Dosage has not been established.

Side effect: Akathisia, parkinsonian extrapyramidal effects, anticholinergic effects (constipation, decreased sweating, dry mouth, dizziness, drowsiness), nasal congestion, change in menstrual period, decreased sexual ability, fever, hypertrophic papilate of the tongue, photophobia, swelling or pain in breasts, weight gain, tardive dyskinesia or tardive dystonia, dizziness, nausea and vomiting, stomach pain, trembling of fingers and hands

Information on the shelf life: 2 years